About Regulus Therapeutics (NASDAQ:RGLS)
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-0.865671641791045
Forward P/E Ratio-1.13
Sales & Book Value
Annual Sales$1.19 million
Price / Sales101.34
Price / CashN/A
Book Value$1.06 per share
Price / Book1.09
Return on Equity-189.71%
Return on Assets-92.92%
Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions
What is Regulus Therapeutics' stock symbol?
Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."
How were Regulus Therapeutics' earnings last quarter?
Regulus Therapeutics Inc (NASDAQ:RGLS) posted its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.02. The biopharmaceutical company earned $0.48 million during the quarter, compared to analyst estimates of $0.50 million. Regulus Therapeutics had a negative net margin of 107,606.96% and a negative return on equity of 189.71%. View Regulus Therapeutics' Earnings History.
When will Regulus Therapeutics make its next earnings announcement?
Where is Regulus Therapeutics' stock going? Where will Regulus Therapeutics' stock price be in 2018?
7 Wall Street analysts have issued 1-year target prices for Regulus Therapeutics' shares. Their forecasts range from $1.00 to $4.00. On average, they anticipate Regulus Therapeutics' share price to reach $2.70 in the next year. View Analyst Ratings for Regulus Therapeutics.
What are Wall Street analysts saying about Regulus Therapeutics stock?
Here are some recent quotes from research analysts about Regulus Therapeutics stock:
- 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (1/25/2018)
- 2. Needham & Company LLC analysts commented, "Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it." (11/14/2017)
Who are some of Regulus Therapeutics' key competitors?
Some companies that are related to Regulus Therapeutics include Sunesis Pharmaceuticals (SNSS), Arsanis (ASNS), Nabriva Therapeutics (NBRV), Corvus Pharmaceuticals (CRVS), Bio-Path (BPTH), CTI BioPharma (CTIC), Compugen (CGEN), ArQule (ARQL), Galectin Therapeutics (GALT), Merrimack Pharmaceuticals (MACK), Pluristem Therapeutics (PSTI), Zynerba Pharmaceuticals (ZYNE), Silence Therapeutics (SLN), Asterias Biotherapeutics (AST), Organovo (ONVO), Checkpoint Therapeutics (CKPT), Bioline RX (BLRX) and Oramed Pharmaceuticals (ORMP).
Who are Regulus Therapeutics' key executives?
Regulus Therapeutics' management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Chairman of the Board (Age 68)
- Joseph P. Hagan, President, Chief Executive Officer, Principal Executive Officer, Director (Age 48)
- Daniel Chevallard, Chief Financial Officer, Principal Financial and Accounting Officer
- Mark Deeg, Chief Medical Officer
- B. Lynne Parshall J.D., Director (Age 63)
- Douglas E. Williams Ph.D., Director (Age 59)
- David Baltimore Ph.D., Independent Director (Age 79)
- Mark G. Foletta CPA, Independent Director (Age 55)
- William H. Rastetter Ph.D., Independent Director (Age 68)
Who owns Regulus Therapeutics stock?
Regulus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BVF Inc. IL (13.44%), Broadfin Capital LLC (1.45%), Ascend Capital LLC (0.98%), Candriam Luxembourg S.C.A. (0.48%), Wells Fargo & Company MN (0.38%) and Victory Capital Management Inc. (0.32%). Company insiders that own Regulus Therapeutics stock include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.
Who sold Regulus Therapeutics stock? Who is selling Regulus Therapeutics stock?
Who bought Regulus Therapeutics stock? Who is buying Regulus Therapeutics stock?
Regulus Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Ascend Capital LLC, Renaissance Technologies LLC and Victory Capital Management Inc.. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.
How do I buy Regulus Therapeutics stock?
Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regulus Therapeutics' stock price today?
One share of Regulus Therapeutics stock can currently be purchased for approximately $1.16.
How big of a company is Regulus Therapeutics?
Regulus Therapeutics has a market capitalization of $116.57 million and generates $1.19 million in revenue each year. The biopharmaceutical company earns $-81,830,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. Regulus Therapeutics employs 97 workers across the globe.
How can I contact Regulus Therapeutics?
Regulus Therapeutics' mailing address is 10614 Science Center Dr, SAN DIEGO, CA 92121-1150, United States. The biopharmaceutical company can be reached via phone at +1-858-2026300 or via email at [email protected]
MarketBeat Community Rating for Regulus Therapeutics (RGLS)MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Regulus Therapeutics (NASDAQ:RGLS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.43||2.38||2.29||2.29|
|Ratings Breakdown: ||0 Sell Rating(s)|
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$2.70||$2.70||$2.88||$4.10|
|Price Target Upside: ||92.86% upside||92.86% upside||215.93% upside||340.39% upside|
Regulus Therapeutics (NASDAQ:RGLS) Consensus Price Target History
Regulus Therapeutics (NASDAQ:RGLS) Analyst Ratings History
(Data available from 2/24/2016 forward)
Regulus Therapeutics (NASDAQ:RGLS) Earnings History and Estimates Chart
Regulus Therapeutics (NASDAQ RGLS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||($0.18)||($0.18)||$0.02 million||$0.02 million||View||N/A|
|8/1/2017||Q2 2017||($0.31)||($0.41)||$0.02 million||$0.02 million||View||Listen|
|5/4/2017||Q1 2017||($0.33)||($0.38)||$0.02 million||$0.02 million||View||N/A|
|3/2/2017||Q4 2016||($0.37)||($0.38)||$0.20 million||$0.02 million||View||Listen|
|11/1/2016||Q3 2016||($0.39)||($0.37)||$0.50 million||$0.20 million||View||N/A|
|8/2/2016||Q216||($0.38)||($0.40)||$0.50 million||$0.48 million||View||Listen|
|5/2/2016||Q1||($0.33)||($0.40)||$2.25 million||$0.49 million||View||Listen|
|2/22/2016||Q415||($0.25)||($0.14)||$5.09 million||$10.90 million||View||Listen|
|11/5/2015||Q315||($0.37)||($0.25)||$3.57 million||$1.87 million||View||N/A|
|8/4/2015||Q215||($0.29)||($0.41)||$2.40 million||$3.80 million||View||N/A|
|5/7/2015||($0.26)||($0.25)||$3.38 million||$4.20 million||View||Listen|
|2/18/2015||($0.21)||($0.47)||$2.24 million||$4.22 million||View||Listen|
|11/5/2014||($0.23)||($0.23)||$2.76 million||$1.08 million||View||Listen|
|8/6/2014||Q214||($0.19)||($0.29)||$3.20 million||$0.74 million||View||N/A|
|5/8/2014||($0.14)||($0.30)||$3.80 million||$1.63 million||View||N/A|
|2/27/2014||($0.13)||($0.11)||$3.69 million||$5.45 million||View||N/A|
|11/13/2013||Q3 2013||($0.16)||($0.07)||$3.56 million||$6.12 million||View||N/A|
|8/13/2013||2Q13||($0.14)||($0.20)||$3.44 million||$4.80 million||View||N/A|
|5/14/2013||Q1 2013||($0.09)||($0.20)||$2.96 million||$3.24 million||View||N/A|
|2/20/2013||Q412||($0.08)||($0.22)||$3.50 million||$3.24 million||View||N/A|
|11/19/2012||Q312||($15.98)||$3.81 million||$2.80 million||View||N/A|
Regulus Therapeutics (NASDAQ:RGLS) Earnings Estimates
2018 EPS Consensus Estimate: ($0.45)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by MarketBeat.com
Regulus Therapeutics (NASDAQ RGLS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 57.83%
Regulus Therapeutics (NASDAQ RGLS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/25/2017||Daniel R Chevallard||CFO||Buy||54,945||$0.91||$49,999.95||59,415|| |
|7/25/2017||Joseph P Hagan||Insider||Buy||219,780||$0.91||$199,999.80||241,297|| |
|7/25/2017||William H Rastetter||Director||Buy||274,725||$0.91||$249,999.75|| |
|3/22/2017||Stelios Papadopoulos||Director||Buy||500,000||$1.22||$610,000.00||400,677|| |
|3/7/2017||William H Rastetter||Director||Buy||250,000||$1.15||$287,500.00|| |
|3/3/2016||Joseph P Hagan||COO||Buy||10,000||$7.19||$71,900.00||10,000|| |
|2/23/2016||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||1,000,000||$7.18||$7,180,000.00||4,896,716|| |
|7/21/2015||William H Rastetter||Director||Buy||100,000||$10.17||$1,017,000.00|| |
|7/20/2015||William H Rastetter||Director||Buy||38,765||$10.13||$392,689.45|| |
|7/17/2015||Isis Pharmaceuticals Inc||Major Shareholder||Sell||343,133||$10.60||$3,637,209.80|| |
|4/21/2015||Kleanthis G Xanthopoulos||CEO||Sell||200,000||$17.15||$3,430,000.00|| |
|4/13/2015||Bruce L A Carter||Director||Sell||20,000||$17.66||$353,200.00|| |
|3/5/2015||Kleanthis G Xanthopoulos||CEO||Sell||89,230||$20.26||$1,807,799.80|| |
|2/2/2015||Kleanthis G Xanthopoulos||CEO||Sell||5,700||$19.61||$111,777.00|| |
|1/29/2015||Kleanthis G Xanthopoulos||CEO||Sell||145,000||$18.06||$2,618,700.00|| |
|1/28/2015||Neil W Gibson||Insider||Sell||80,000||$18.05||$1,444,000.00|| |
|11/28/2014||Neil W Gibson||Insider||Sell||2,500||$19.30||$48,250.00|| |
|11/3/2014||Isis Pharmaceuticals Inc||Major Shareholder||Sell||1,279,411||$15.94||$20,393,811.34|| |
|10/24/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||113,084||$14.02||$1,585,437.68|| |
|10/22/2014||Neil W Gibson||Insider||Sell||3,300||$14.44||$47,652.00|| |
|10/10/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||2,000||$6.41||$12,820.00|| |
|10/10/2014||Isis Pharmaceuticals Inc||Director||Sell||10,050||$6.56||$65,928.00|| |
|10/9/2014||Isis Pharmaceuticals Inc||Director||Sell||4,750||$6.58||$31,255.00|| |
|10/8/2014||Isis Pharmaceuticals Inc||Director||Sell||3,300||$6.63||$21,879.00|| |
|10/3/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||10,300||$6.74||$69,422.00|| |
|10/3/2014||Isis Pharmaceuticals Inc||Director||Sell||3,300||$6.88||$22,704.00|| |
|10/2/2014||Isis Pharmaceuticals Inc||Director||Sell||3,750||$6.64||$24,900.00|| |
|10/1/2014||Isis Pharmaceuticals Inc||Director||Sell||3,250||$6.71||$21,807.50|| |
|9/30/2014||Kleanthis G Xanthopoulos||CEO||Sell||2,300||$7.02||$16,146.00|| |
|9/26/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||2,500||$7.04||$17,600.00|| |
|9/26/2014||Isis Pharmaceuticals Inc||Director||Sell||8,750||$7.13||$62,387.50|| |
|9/25/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||2,500||$7.12||$17,800.00|| |
|9/24/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||3,750||$7.19||$26,962.50|| |
|9/19/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||7,700||$7.31||$56,287.00|| |
|9/19/2014||Isis Pharmaceuticals Inc||Director||Sell||4,100||$7.22||$29,602.00|| |
|9/18/2014||Isis Pharmaceuticals Inc||Director||Sell||1,500||$7.40||$11,100.00|| |
|9/17/2014||Isis Pharmaceuticals Inc||Director||Sell||2,100||$7.43||$15,603.00|| |
|9/12/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||8,900||$7.85||$69,865.00|| |
|9/12/2014||Isis Pharmaceuticals Inc||Director||Sell||3,500||$7.96||$27,860.00|| |
|9/12/2014||Neil W Gibson||Insider||Sell||4,200||$8.01||$33,642.00|| |
|9/11/2014||Isis Pharmaceuticals Inc||Director||Sell||3,400||$7.83||$26,622.00|| |
|9/10/2014||Isis Pharmaceuticals Inc||Director||Sell||2,000||$7.70||$15,400.00|| |
|9/5/2014||Isis Pharmaceuticals Inc||Director||Sell||10,050||$7.07||$71,053.50|| |
|8/29/2014||Isis Pharmaceuticals Inc||Director||Sell||1,500||$6.84||$10,260.00|| |
|8/28/2014||Isis Pharmaceuticals Inc||Director||Sell||2,000||$6.96||$13,920.00|| |
|8/28/2014||Kleanthis G Xanthopoulos||CEO||Sell||3,505||$7.06||$24,745.30|| |
|8/27/2014||Isis Pharmaceuticals Inc||Director||Sell||1,500||$7.21||$10,815.00|| |
|8/22/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||5,250||$6.75||$35,437.50|| |
|8/21/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||2,500||$6.89||$17,225.00|| |
|8/20/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||3,000||$7.14||$21,420.00|| |
|8/15/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||1,450||$6.98||$10,121.00|| |
|8/14/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||1,750||$7.04||$12,320.00|| |
|8/13/2014||Alnylam Pharmaceuticals, Inc.||Major Shareholder||Sell||2,250||$7.02||$15,795.00|| |
|8/8/2014||Isis Pharmaceuticals Inc||Director||Sell||1,850||$6.80||$12,580.00|| |
|8/7/2014||Isis Pharmaceuticals Inc||Director||Sell||2,600||$6.66||$17,316.00|| |
|8/6/2014||Isis Pharmaceuticals Inc||Director||Sell||3,150||$7.08||$22,302.00|| |
|8/1/2014||Isis Pharmaceuticals Inc||Director||Sell||2,600||$6.21||$16,146.00|| |
|7/31/2014||Isis Pharmaceuticals Inc||Director||Sell||1,750||$6.42||$11,235.00|| |
|7/30/2014||Isis Pharmaceuticals Inc||Director||Sell||1,000||$6.60||$6,600.00|| |
|7/25/2014||Isis Pharmaceuticals Inc||Director||Sell||1,700||$6.55||$11,135.00|| |
|7/24/2014||Isis Pharmaceuticals Inc||Director||Sell||1,850||$6.81||$12,598.50|| |
|7/23/2014||Isis Pharmaceuticals Inc||Director||Sell||1,700||$6.88||$11,696.00|| |
|7/18/2014||Isis Pharmaceuticals Inc||Director||Sell||5,000||$6.80||$34,000.00|| |
|7/17/2014||Isis Pharmaceuticals Inc||Director||Sell||5,000||$6.58||$32,900.00|| |
|7/16/2014||Isis Pharmaceuticals Inc||Director||Sell||3,500||$6.59||$23,065.00|| |
|7/11/2014||Isis Pharmaceuticals Inc||Director||Sell||1,750||$6.48||$11,340.00|| |
|7/10/2014||Isis Pharmaceuticals Inc||Director||Sell||4,500||$6.69||$30,105.00|| |
|7/9/2014||Isis Pharmaceuticals Inc||Director||Sell||1,800||$7.08||$12,744.00|| |
|2/4/2014||Sanofi||major shareholder||Buy||1,303,780||$7.67||$9,999,992.60|| |
|1/21/2014||Neil Gibson||Insider||Sell||4,421||$8.09||$35,765.89||50,000|| |
|1/17/2014||Neil Gibson||Insider||Sell||4,479||$8.15||$36,503.85||50,000|| |
|1/16/2014||Neil Gibson||Insider||Sell||1,100||$8.03||$8,833.00||50,000|| |
|1/2/2014||Kleanthis Xanthopoulos||CEO||Sell||3,505||$7.25||$25,411.25|| |
|10/10/2012||Stanley T Crooke||Director||Buy||750,000||$4.00||$3,000,000.00|| |
Regulus Therapeutics (NASDAQ RGLS) News Headlines
Regulus Therapeutics (NASDAQ:RGLS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Regulus Therapeutics (NASDAQ:RGLS) Income Statement, Balance Sheet and Cash Flow Statement
Regulus Therapeutics (NASDAQ RGLS) Stock Chart for Saturday, February, 24, 2018